JP2020510668A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510668A5
JP2020510668A5 JP2019547579A JP2019547579A JP2020510668A5 JP 2020510668 A5 JP2020510668 A5 JP 2020510668A5 JP 2019547579 A JP2019547579 A JP 2019547579A JP 2019547579 A JP2019547579 A JP 2019547579A JP 2020510668 A5 JP2020510668 A5 JP 2020510668A5
Authority
JP
Japan
Prior art keywords
carbonitrile
pyrrolo
pyrazol
pyrimidin
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510668A (ja
JP6978507B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062148 external-priority patent/WO2018094137A1/en
Publication of JP2020510668A publication Critical patent/JP2020510668A/ja
Publication of JP2020510668A5 publication Critical patent/JP2020510668A5/ja
Priority to JP2021183048A priority Critical patent/JP7360434B2/ja
Application granted granted Critical
Publication of JP6978507B2 publication Critical patent/JP6978507B2/ja
Priority to JP2023169299A priority patent/JP7592814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547579A 2016-11-18 2017-11-17 Cftr増強物質としてのピロロピリミジン Active JP6978507B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021183048A JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン
JP2023169299A JP7592814B2 (ja) 2016-11-18 2023-09-29 Cftr増強物質としてのピロロピリミジン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
US62/423,919 2016-11-18
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183048A Division JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン

Publications (3)

Publication Number Publication Date
JP2020510668A JP2020510668A (ja) 2020-04-09
JP2020510668A5 true JP2020510668A5 (enExample) 2020-12-17
JP6978507B2 JP6978507B2 (ja) 2021-12-08

Family

ID=62144793

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547579A Active JP6978507B2 (ja) 2016-11-18 2017-11-17 Cftr増強物質としてのピロロピリミジン
JP2021183048A Active JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン
JP2023169299A Active JP7592814B2 (ja) 2016-11-18 2023-09-29 Cftr増強物質としてのピロロピリミジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021183048A Active JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン
JP2023169299A Active JP7592814B2 (ja) 2016-11-18 2023-09-29 Cftr増強物質としてのピロロピリミジン

Country Status (21)

Country Link
US (5) US10301315B2 (enExample)
EP (2) EP4424311A3 (enExample)
JP (3) JP6978507B2 (enExample)
KR (2) KR102585398B1 (enExample)
CN (2) CN110337294B (enExample)
AU (2) AU2017362350B2 (enExample)
CL (1) CL2019001334A1 (enExample)
CO (1) CO2019005993A2 (enExample)
CR (1) CR20190292A (enExample)
DO (1) DOP2019000126A (enExample)
EC (1) ECSP19043120A (enExample)
ES (1) ES2983686T3 (enExample)
IL (3) IL314404B2 (enExample)
MX (2) MX387203B (enExample)
PE (1) PE20200739A1 (enExample)
PH (1) PH12019501098A1 (enExample)
PL (1) PL3541390T3 (enExample)
RU (2) RU2021129721A (enExample)
SG (1) SG10202106949XA (enExample)
UA (1) UA125400C2 (enExample)
WO (1) WO2018094137A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3393465A1 (en) * 2015-12-22 2018-10-31 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UA125400C2 (uk) * 2016-11-18 2022-03-02 Цистік Фіброзис Фаундейшн Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr)
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
AU2017378324B2 (en) * 2016-12-16 2021-09-02 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as CFTR potentiators
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (en) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
KR20220019015A (ko) * 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
TW202116312A (zh) 2019-07-15 2021-05-01 瑞士商諾華公司 (s)—3—胺基—6—甲氧基—n—(3,3,3—三氟—2—羥基—2—甲基丙基)—5—(三氟甲基)吡啶甲醯胺配製物
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
BR112023002651A2 (pt) 2020-08-20 2023-04-04 Univ Leland Stanford Junior Métodos de tratamento de doenças respiratórias definidas por hipersecreção de muco
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含cftr調節劑化合物之點眼用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2002096867A2 (en) 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
BRPI0708779A2 (pt) * 2006-03-11 2011-06-14 Vernalis R & D derivados de pirrolopirimidina utilizados como inibidores de hsp90
KR101499783B1 (ko) * 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
DK2385832T3 (en) 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
US20130123281A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
UA125400C2 (uk) 2016-11-18 2022-03-02 Цистік Фіброзис Фаундейшн Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr)

Similar Documents

Publication Publication Date Title
JP2020510668A5 (enExample)
USD821188S1 (en) Towel clip
USD786655S1 (en) Carabiner
NO2025051I1 (no) vanzacaftor, or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof
USD809987S1 (en) Leveling block
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
CN110139865A (zh) Fgfr抑制剂
JP2013173781A5 (enExample)
USD755903S1 (en) Building block
USD724503S1 (en) Front bumper
USD818056S1 (en) Building block
JP2017520613A5 (enExample)
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
CA2902403C (en) Pde3/pde4 inhibitor/muscarinic receptor antagonist combination
LT3986561T (lt) Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
USD754551S1 (en) Locating and tracking tool
MX2016001639A (es) Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
USD755904S1 (en) Building block
USD754260S1 (en) Building block
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
CN109843873A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
CN109790159A (zh) 抗流感病毒嘧啶衍生物
USD755902S1 (en) Building block
HK1254343A1 (zh) 药物制剂
WO2016205738A3 (en) Delivery systems for controlled drug release